
Tepezza Leads
Connect with patients who suffered permanent hearing loss or tinnitus after Tepezza infusions for thyroid eye disease.
Tepezza Hearing Loss & Tinnitus Litigation
Tepezza (teprotumumab) is an infusion drug approved by the FDA in January 2020 to treat thyroid eye disease (TED). Lawsuits allege the manufacturer, Horizon Therapeutics (now part of Amgen), failed to adequately warn patients and physicians that the drug can cause permanent hearing loss, tinnitus, and other hearing-related injuries. The cases are consolidated in federal multidistrict litigation MDL 3079, before Judge Thomas M. Durkin in the Northern District of Illinois. As of 2026 the litigation remains active, with bellwether proceedings underway and new claimants still being accepted.
Associated Conditions
- Permanent or partial hearing loss
- Tinnitus (persistent ringing in the ears)
- Eustachian tube dysfunction
- Autophony (hearing your own voice abnormally loud)
- Plugged or blocked ear sensation
- Muffled hearing or hyperacusis
- Sensorineural hearing impairment
Claimant Eligibility
- Received one or more Tepezza (teprotumumab) infusions for thyroid eye disease
- Diagnosed with hearing loss, tinnitus, or another hearing-related injury after treatment
- Symptoms appeared during or after the Tepezza infusion course
- Hearing damage can be documented through medical or audiology records
- Claim filed within the applicable statute of limitations for your state
Why Law Firms Choose Us
Exclusive Leads
Every lead is yours alone. We never resell or share claimant information with competing firms, guaranteeing you first-mover advantage on every case.
Pre-Qualified Claimants
Our intake specialists screen every potential claimant against your specific case criteria before delivery, so your team only speaks with viable cases.
Live Transfer
Qualified claimants are transferred directly to your intake team in real time, maximizing conversion rates and reducing time-to-retainer.
Running a Tepezza mass tort marketing campaign
Common questions from law firms about Tepezza lead generation and campaign management.
- What does a Tepezza mass tort marketing campaign include?
- A Tepezza mass tort marketing campaign from Mass Tort Agency covers channel strategy across Meta, Google/PPC, OTT, and mass tort SEO; compliant ad creative; TCPA-verified intake; claimant qualification against your Tepezza case criteria; and signed-retainer reporting. Performance is measured on cost per signed retainer, not raw lead volume.
- Are Tepezza leads exclusive to my firm?
- Yes. Every Tepezza lead is delivered to one firm only — never resold, syndicated, or shared with competing firms. Your firm owns the contact data, consent records, and call recordings.
- How are Tepezza claimants qualified before delivery?
- Each Tepezza claimant is screened against tort-specific facts (exposure windows, injury markers, and state eligibility) and carries a TrustedForm or Jornaya consent token captured under the FCC one-to-one consent standard before the lead reaches your intake team.
- How is a Tepezza campaign priced?
- Campaigns are quoted and reported on cost per signed retainer (CPSR), so spend ties directly to signed cases rather than lead count. You can scale volume up or down by tort as your docket capacity changes.
See how every lead is qualified on our mass tort leads page, or compare providers in our top mass tort marketing firms guide.